homotaurine; 3-Amino-1-propanesulfonic acid; tramiprosate; ALZ-801

Indications

• phase 3 clinical trials for Alzheimer's disease
  • may be most useful for patients with 2 apoE4 alleles
  • of no benefit for patients without apoE4 alleles

Dosage

• 150 mg BID

Mechanism of action

• blocks aggregation of beta-amyloid monomers into toxic oligomers
• gene-dose effect for APOE4 carriers

More general terms

• amine
• sulfonic acid
• Alzheimer's agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=1646
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23663660